---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-011573"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2024-04-10T23:59:59+00:00"
generated_at: "2026-06-04T00:25:50.294562+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Monopar initiates Phase 1 dosimetry trial for MNPR-101-Zr in advanced cancers

## Summary
- Trial open for enrollment at Melbourne Theranostic Innovation Centre; led by Prof. Rodney Hicks.
- Evaluating safety/dosimetry in up to 12 advanced cancer patients using total-body PET/CT scanner.
- MNPR-101 targets uPAR expressed on pancreatic, breast, colorectal, and bladder tumors.
- Preclinical data show specific tumor uptake; if Phase 1 positive, plan to test MNPR-101 with therapeutic Ac-225.

## SEC filing metadata
- accession: 0001437749-24-011573
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2024-04-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774924011573/0001437749-24-011573-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774924011573/mnpr20240402_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-011573
- JSON: https://secwatch.observer/filing/0001437749-24-011573.json
- Plain text: https://secwatch.observer/filing/0001437749-24-011573.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.